BIRC5 and psoriasis: Multiple studies have found aberrant survivin expression in rheumatoid arthritis (RA) (50), inflammatory bowel disease (IBD) (51), psoriasis (52), systemic Lupus erythematosus (SLE) (53), and multiple sclerosis (MS) (54).